Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Abstract Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previou...

Full description

Bibliographic Details
Main Authors: Mariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai, Sarah Mougalian
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Breast Cancer Research
Subjects:
Everolimus
Exemestane
CDK4/6 inhibitors
Metastatic hormone-positive HER2-negative breast cancer
Sequence of therapy
Endocrine therapy
Online Access:https://doi.org/10.1186/s13058-021-01394-y

Internet

https://doi.org/10.1186/s13058-021-01394-y

Similar Items